Palladium Partners LLC Buys 41 Shares of Zimmer Biomet Holdings, Inc. (ZBH)

Palladium Partners LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,501 shares of the medical equipment provider’s stock after buying an additional 41 shares during the period. Palladium Partners LLC’s holdings in Zimmer Biomet Holdings were worth $321,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Retirement Systems of Alabama increased its position in Zimmer Biomet Holdings by 0.4% in the second quarter. Retirement Systems of Alabama now owns 97,564 shares of the medical equipment provider’s stock valued at $12,527,000 after buying an additional 355 shares in the last quarter. IFP Advisors Inc increased its position in Zimmer Biomet Holdings by 22.4% in the second quarter. IFP Advisors Inc now owns 2,077 shares of the medical equipment provider’s stock valued at $267,000 after buying an additional 380 shares in the last quarter. Korea Investment CORP increased its position in Zimmer Biomet Holdings by 11.8% in the second quarter. Korea Investment CORP now owns 293,848 shares of the medical equipment provider’s stock valued at $37,730,000 after buying an additional 31,052 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in Zimmer Biomet Holdings by 123.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 98,345 shares of the medical equipment provider’s stock valued at $12,628,000 after buying an additional 54,390 shares in the last quarter. Finally, Stratos Wealth Partners LTD. increased its position in Zimmer Biomet Holdings by 41.6% in the second quarter. Stratos Wealth Partners LTD. now owns 25,183 shares of the medical equipment provider’s stock valued at $3,234,000 after buying an additional 7,401 shares in the last quarter. Hedge funds and other institutional investors own 82.84% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down 0.93% during midday trading on Friday, reaching $111.38. The company’s stock had a trading volume of 1,036,099 shares. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49. The stock has a market cap of $22.52 billion, a price-to-earnings ratio of 31.72 and a beta of 1.20. The stock has a 50-day moving average price of $122.63 and a 200-day moving average price of $121.15.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.

ILLEGAL ACTIVITY NOTICE: This article was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/palladium-partners-llc-buys-41-shares-of-zimmer-biomet-holdings-inc-zbh-updated.html.

Several equities analysts have commented on the company. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. BidaskClub downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. BMO Capital Markets raised their price objective on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Leerink Swann raised their price objective on Zimmer Biomet Holdings from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $136.90.

In related news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply